HRP20201844T1 - Biodostupni poliamini - Google Patents

Biodostupni poliamini Download PDF

Info

Publication number
HRP20201844T1
HRP20201844T1 HRP20201844TT HRP20201844T HRP20201844T1 HR P20201844 T1 HRP20201844 T1 HR P20201844T1 HR P20201844T T HRP20201844T T HR P20201844TT HR P20201844 T HRP20201844 T HR P20201844T HR P20201844 T1 HRP20201844 T1 HR P20201844T1
Authority
HR
Croatia
Prior art keywords
salt
solid
solid residue
salt according
dosage form
Prior art date
Application number
HRP20201844TT
Other languages
English (en)
Inventor
Mark R. Burns
Original Assignee
Aminex Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aminex Therapeutics, Inc. filed Critical Aminex Therapeutics, Inc.
Publication of HRP20201844T1 publication Critical patent/HRP20201844T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126Acids containing more than four carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (12)

1. Sol dvo-protoniranog oblika poliamina formule AMXT 1501 i deprotonirane kaprinske kiseline, pri čemu sol ima dva mola deprotonirane kaprinske kiseline za svaki mol protoniranog AMXT 1501 [image]
2. Sol prema zahtjevu 1, koja ima strukturu [image]
3. Sol prema zahtjevu 1 u mješavini s najviše 5 mas.% bilo koje druge krute ili tekuće kemikalije.
4. Farmaceutski pripravak koji sadrži sol prema zahtjevu 1.
5. Farmaceutski pripravak prema zahtjevu 4 naznačen time što pripravak ima oralni oblik krutog doziranja.
6. Postupak koji obuhvaća: kombiniranje poliaminskog farmaceutskog sredstva, hidrofobne karboksilne kiseline i otapala kako bi se dobila otopina; i izoliranje krutog ostatka iz otopine, pri čemu kruti ostatak sadrži sol prema zahtjevu 1.
7. Postupak prema zahtjevu 6, naznačen time što otapalo sadrži vodu, metanol ili njihovu kombinaciju.
8. Postupak prema zahtjevu 6, naznačen time što se 1.8-2.2 mola hidrofobne karboksilne kiseline kombinira sa svakih 1.0 mola poliaminskog farmaceutskog sredstva.
9. Postupak prema zahtjevu 6 naznačen time što kruti ostatak nastaje taloženjem iz otopine.
10. Postupak prema zahtjevu 6 nadalje obuhvaća formuliranje krutog ostatka ili njegovog dijela u lijek oblika krutog doziranja.
11. Sol prema zahtjevu 1 za uporabu u postupku liječenja raka, navedeni postupak sadrži davanje subjektu kojem je to potrebno terapeutski učinkovitu količinu soli.
12. Sol prema zahtjevu 11, naznačena time što se terapijski učinkovita količina soli daje subjektu kao oblik krutog doziranja.
HRP20201844TT 2016-03-25 2020-11-20 Biodostupni poliamini HRP20201844T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313657P 2016-03-25 2016-03-25
PCT/US2017/023250 WO2017165313A1 (en) 2016-03-25 2017-03-20 Bioavailable polyamines
EP17770923.5A EP3432914B1 (en) 2016-03-25 2017-03-20 Bioavailable polyamines

Publications (1)

Publication Number Publication Date
HRP20201844T1 true HRP20201844T1 (hr) 2021-04-02

Family

ID=59899774

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201844TT HRP20201844T1 (hr) 2016-03-25 2020-11-20 Biodostupni poliamini

Country Status (20)

Country Link
US (3) US10632145B2 (hr)
EP (2) EP3432914B1 (hr)
JP (1) JP6949098B2 (hr)
KR (1) KR102454783B1 (hr)
CN (1) CN109069594B (hr)
AU (1) AU2017236905B2 (hr)
CA (1) CA3015849A1 (hr)
CY (1) CY1123636T1 (hr)
DK (2) DK3432914T3 (hr)
EA (1) EA037149B1 (hr)
ES (2) ES2836289T3 (hr)
HR (1) HRP20201844T1 (hr)
HU (1) HUE052620T2 (hr)
IL (1) IL261512A (hr)
LT (1) LT3432914T (hr)
MX (1) MX2018010768A (hr)
PL (1) PL3432914T3 (hr)
PT (1) PT3432914T (hr)
SI (1) SI3432914T1 (hr)
WO (1) WO2017165313A1 (hr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052620T2 (hu) 2016-03-25 2021-05-28 Aminex Therapeutics Inc Biológiailag hozzáférhetõ poliaminok
WO2022072586A1 (en) 2020-09-30 2022-04-07 Aminex Therapeutics, Inc. Combination drug substance of polyamine transport inhibitor and dfmo
US20230321012A1 (en) * 2021-12-01 2023-10-12 Aminex Therapeutics, Inc. Methods To Treat Cancer With AMXT 1501 and DFMO

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3517M (fr) * 1962-12-07 1965-09-06 Hoffmann La Roche Médicament a base de compositions vitaminées.
US4309442A (en) 1977-07-11 1982-01-05 Merrell Toraude Et Compagnie Method for controlling fertility in mammals
US4590288A (en) 1983-06-29 1986-05-20 Exxon Research And Engineering Co. Bi- or polymetallic coordination complex
HU200093B (en) 1983-12-20 1990-04-28 Adam Kovacs Process for production of medical compositions against tumour
EP0187332B1 (en) 1985-01-10 1989-02-01 Molecular Diagnostics, Inc. Photochemical method of labelling nucleic acids for detection in hybridization assays
US4818770A (en) 1986-10-22 1989-04-04 Boyce Thompson Institute For Plant Research Prevention of a plant disease by specific inhibition of fungal polyamine biosynthesis
US5342945A (en) 1986-12-02 1994-08-30 University Of Florida Research Foundation, Inc. Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
JP3072108B2 (ja) 1988-12-09 2000-07-31 ダイセル化学工業株式会社 新規なポリアミン化合物及びグルタミン酸レセプター遮断剤
EP0597830A1 (en) 1989-07-03 1994-05-25 New York University Nyu Medical Center Use of polyamines as ionic-channel regulating agents
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5561136A (en) 1990-12-13 1996-10-01 Merrell Pharmaceuticals Inc. Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5312928A (en) 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US6743419B1 (en) 1992-12-22 2004-06-01 The Gillette Company Method of reducing hair growth employing sulfhydryl active compounds
US5648394A (en) 1993-05-27 1997-07-15 Boxall; Brian Alfred Topical composition for inhibiting hair growth
US5541230A (en) 1993-11-05 1996-07-30 Us Health Therapeutic polyamines
JPH09509484A (ja) 1994-02-08 1997-09-22 エヌピーエス・ファルマシューティカルズ,インコーポレイテッド 神経障害および神経病の治療に有用な受容体作動性カルシウムチャネル上の新規部位で活性な化合物
KR19980701677A (ko) 1995-01-25 1998-06-25 에이치. 캐서린 화이트 팽창 쿠션 및 그 제조 방법
US5583239A (en) 1995-05-30 1996-12-10 Lehigh University Antimicrobial sterol conjugates
JPH09235271A (ja) 1996-02-29 1997-09-09 Suntory Ltd ポリアミン誘導体
AU723825B2 (en) 1996-03-14 2000-09-07 Msd Consumer Care, Inc. Sunless tanning composition and method
US6172261B1 (en) 1997-07-15 2001-01-09 Oridigm Corporation Polyamine analogues as therapeutic and diagnostic agents
US6646149B1 (en) 1997-07-15 2003-11-11 Nicolaas M. J. Vermeulin Polyamine analogues as therapeutic and diagnostic agents
US7208528B1 (en) 1997-07-15 2007-04-24 Mediquest Therapeutics, Inc. Polyamine analogues as therapeutic and diagnostic agents
EP1003715A1 (en) 1998-04-21 2000-05-31 Universite Laval Polyamine transport inhibitors
AU1998899A (en) 1998-12-10 2000-06-26 Ilex Oncology, Inc. Polyamine transport inhibitors
ATE308515T1 (de) 1999-02-05 2005-11-15 Oridigm Corp Antizymmodulatoren sowie deren verwendung
CA2318004A1 (en) 1999-09-15 2001-03-15 Oridigm Corporation Novel polyamine analogues as therapeutic and diagnostic agents
US6235737B1 (en) 2000-01-25 2001-05-22 Peter Styczynski Reduction of hair growth
US6872852B2 (en) 2000-03-24 2005-03-29 Mediquest Therapeutics, Inc. Polyamine analogues as cytotoxic agents
USRE43327E1 (en) 2001-01-08 2012-04-24 Aminex Therapeutics, Inc. Hydrophobic polyamine analogs and methods for their use
KR100859929B1 (ko) * 2001-01-08 2008-09-23 메디퀘스트 세라퓨틱스 아이엔씨 소수성 폴리아민 유사체들과 그 사용
US7432302B2 (en) 2001-01-08 2008-10-07 Mediquest Therapeutics, Inc. Composition containing polyamine transport inhibitor and use thereof
US6914079B2 (en) 2002-09-23 2005-07-05 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme frameshifting
US7144920B2 (en) 2002-09-23 2006-12-05 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme frameshifting
US6919483B2 (en) 2003-05-23 2005-07-19 Mediquest Therapeutics, Inc. Immunomodulation with novel pharmaceutical compositions
WO2007001455A2 (en) 2004-11-12 2007-01-04 Mediquest Therapeutics, Inc. Hydrophobic polyamine amides as potent lipopolysaccharide sequestrants
US7199267B1 (en) 2005-10-21 2007-04-03 Mediquest Therapeutics, Inc. Recognition of oligiosaccaride molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases
US7411002B2 (en) 2006-06-07 2008-08-12 The University Of Kansas Polycationic sulfonamides and use thereof
WO2009110939A2 (en) 2007-12-10 2009-09-11 Massachusetts Institute Of Technology Drug delivery system for pharmaceuticals and radiation
US8366600B2 (en) 2008-06-19 2013-02-05 Nupathe Inc. Polyamine enhanced formulations for triptan compound iontophoresis
DE102009000505A1 (de) * 2009-01-30 2010-08-05 Evonik Goldschmidt Gmbh Zusammensetzungen enthaltend Reaktionsprodukte aus Alkylamidoaminen, Alkylaminoimidazolinen und freiem Amin sowie deren Verwendung
ES2715173T3 (es) 2009-07-16 2019-06-03 Pathologica Llc Producto farmacéutico para administración oral que comprende MGBG y métodos de tratamiento de enfermedades
US20110256161A1 (en) 2010-04-19 2011-10-20 Aminex Therapeutics Inc. Methods for enhancing immune response
CN104540813A (zh) * 2012-06-27 2015-04-22 默沙东公司 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
US9439433B2 (en) * 2013-05-22 2016-09-13 Curza Global, Llc Compositions and methods comprising a biocidal polyamine
HUE052620T2 (hu) 2016-03-25 2021-05-28 Aminex Therapeutics Inc Biológiailag hozzáférhetõ poliaminok

Also Published As

Publication number Publication date
US20230088829A1 (en) 2023-03-23
ES2955255T3 (es) 2023-11-29
KR20180123133A (ko) 2018-11-14
EP3432914B1 (en) 2020-09-23
EP3785706B1 (en) 2023-06-07
HUE052620T2 (hu) 2021-05-28
PL3432914T3 (pl) 2021-03-08
EA201892175A1 (ru) 2019-02-28
JP2019513153A (ja) 2019-05-23
LT3432914T (lt) 2020-12-10
CN109069594A (zh) 2018-12-21
KR102454783B1 (ko) 2022-10-13
IL261512A (en) 2018-10-31
US10632145B2 (en) 2020-04-28
US11395834B2 (en) 2022-07-26
MX2018010768A (es) 2018-11-29
AU2017236905A1 (en) 2018-09-06
DK3432914T3 (da) 2020-11-30
ES2836289T3 (es) 2021-06-24
JP6949098B2 (ja) 2021-10-13
PT3432914T (pt) 2020-12-24
SI3432914T1 (sl) 2021-01-29
US20200352983A1 (en) 2020-11-12
WO2017165313A1 (en) 2017-09-28
CA3015849A1 (en) 2017-09-28
EP3432914A1 (en) 2019-01-30
CY1123636T1 (el) 2022-03-24
EA037149B1 (ru) 2021-02-11
AU2017236905B2 (en) 2024-03-28
DK3785706T3 (da) 2023-09-11
CN109069594B (zh) 2022-03-08
EP3432914A4 (en) 2019-11-13
US20190008892A1 (en) 2019-01-10
EP3785706A1 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
HRP20201844T1 (hr) Biodostupni poliamini
HRP20171512T1 (hr) Derivati betulina
HRP20180007T1 (hr) Formulacija koja sadrži gemcitabin-predlijek
HRP20201043T1 (hr) Spojevi 4-amino-imidazokinolina
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
HRP20201949T1 (hr) 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji
HRP20221294T1 (hr) Neuroaktivni steroidi, njihovi pripravci i uporabe
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
HRP20150770T1 (hr) Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin
HRP20191523T1 (hr) Paraziticidne kombinacije spirocikličkog izoksazolina
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
JP2012255026A5 (hr)
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
HRP20211429T1 (hr) Derivati sobetiroma
JP2014129360A5 (hr)
HRP20171515T1 (hr) Spojevi fenoksietilpiperidina
SI3137081T1 (en) BUPRENORFIN DIMER AND ITS USE IN HEALTHY DISEASE DISEASES
RU2018135967A (ru) Интраназальные фармацевтические композиции на основе бензодиазепина
HRP20220683T1 (hr) Liječenje parkinsonove bolesti
HRP20201893T1 (hr) Ciklopiroks, ciklopiroks olamin ili ciklopiroks predlijek za uporabu u liječenju raka mokraćnog mjehura
FR2999086B1 (fr) Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
HRP20201187T1 (hr) Derivat triazolopirazinona koristan kao inhibitor ljudskog pde1
HRP20151340T1 (hr) Derivati tieno[2,3-d] pirimidina i njihova primjena u lijeäśenju aritmije
RU2017134794A (ru) Комбинированная лекарственная форма антагониста мю-опиоидного рецептора и опиоидного средства
HRP20230067T1 (hr) Ligand gaba receptora